Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912386298> ?p ?o ?g. }
- W2912386298 abstract "Background: Cerebral microbleeds (CMBs) are reported to predict recurrent stroke and antithrombotic-related intracerebral hemorrhage (ICH). We characterize CMBs in a well-defined population of embolic strokes of undetermined source (ESUS). Notably, we report for the first time interactions between CMBs and effects of random assignment to anticoagulant therapy. Methods: Subgroup analyses of the NAVIGATE ESUS randomized trial comparing rivaroxaban 15 mg vs. aspirin 100 mg daily were performed. CMBs were rated on T2*-GRE sequences obtained at baseline MRI in 3699 participants (mean age 67y). Multivariable regression analyses were used to identify variables independently associated with CMBs. Cox proportional hazards models were used to estimate the contribution of CMBs to risk of recurrent stroke, ischemic stroke, ICH and all-cause mortality. Analyses followed the intent-to-treat paradigm. Results: CMBs were present in 11% of participants. CMBs were strictly deep in 55%, lobar in 26%, and mixed in 19% of cases. Most (68%) had 1-2 CMBs, 27% had 3-10, and 5% >10. Advancing age (OR per yr 1.0, 95% CI 1.01-1.04), East Asian ethnicity (1.6, 1.0-2.4), hypertension (2.2, 1.5-3.2), multi-territorial ESUS (2.0, 1.4-2.7), chronic infarcts (1.8, 1.4-2.2), and occult ICH (5.2, 2.8-9.9) were independently associated with CMBs. During a median follow-up of 11 months, 5.1% of participants had recurrent stroke (4.8% ischemic stroke; 0.3% ICH) and 1.3% died. The presence of CMBs was associated with a 50% increased risk of recurrent stroke (HR 1.5, 95% CI 1.0-2.3), four-fold risk of ICH (4.2, 1.3-13.9), and two-fold risk of all-cause mortality (2.1, 1.1-4.3), and strictly lobar CMBs with a ~2.5-fold risk of ischemic stroke (2.3, 1.3-4.3). There were no interactions between CMBs and treatment assignments for recurrent stroke (p-value for interaction=0.2), ischemic stroke (p=0.3), or all-cause mortality (p=0.6). The hazard ratio (HR) of ICH on rivaroxaban was similar between persons with CMBs (HR 3.1, 95% CI 0.3 - 30.0) and persons without CMBs (HR 3.0, 95% CI 0.6 - 14.7; interaction p=1.0). Conclusions: CMBs mark an increased risk of recurrent ischemic stroke, ICH and mortality in ESUS, but do not appear to influence effects of rivaroxaban, particularly on the outcome of ICH." @default.
- W2912386298 created "2019-02-21" @default.
- W2912386298 creator A5006528309 @default.
- W2912386298 creator A5009170752 @default.
- W2912386298 creator A5012542087 @default.
- W2912386298 creator A5015783013 @default.
- W2912386298 creator A5025141510 @default.
- W2912386298 creator A5027482892 @default.
- W2912386298 creator A5039490283 @default.
- W2912386298 creator A5039597123 @default.
- W2912386298 creator A5042205473 @default.
- W2912386298 creator A5043035754 @default.
- W2912386298 creator A5047724596 @default.
- W2912386298 creator A5052415437 @default.
- W2912386298 creator A5053088701 @default.
- W2912386298 creator A5055052720 @default.
- W2912386298 creator A5068657718 @default.
- W2912386298 creator A5069793228 @default.
- W2912386298 creator A5076026606 @default.
- W2912386298 creator A5086609118 @default.
- W2912386298 date "2019-02-01" @default.
- W2912386298 modified "2023-10-18" @default.
- W2912386298 title "Abstract 41: Cerebral Microbleeds and the Effect of Anticoagulation on Outcomes in 3699 Patients With Embolic Strokes of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial" @default.
- W2912386298 doi "https://doi.org/10.1161/str.50.suppl_1.41" @default.
- W2912386298 hasPublicationYear "2019" @default.
- W2912386298 type Work @default.
- W2912386298 sameAs 2912386298 @default.
- W2912386298 citedByCount "0" @default.
- W2912386298 crossrefType "journal-article" @default.
- W2912386298 hasAuthorship W2912386298A5006528309 @default.
- W2912386298 hasAuthorship W2912386298A5009170752 @default.
- W2912386298 hasAuthorship W2912386298A5012542087 @default.
- W2912386298 hasAuthorship W2912386298A5015783013 @default.
- W2912386298 hasAuthorship W2912386298A5025141510 @default.
- W2912386298 hasAuthorship W2912386298A5027482892 @default.
- W2912386298 hasAuthorship W2912386298A5039490283 @default.
- W2912386298 hasAuthorship W2912386298A5039597123 @default.
- W2912386298 hasAuthorship W2912386298A5042205473 @default.
- W2912386298 hasAuthorship W2912386298A5043035754 @default.
- W2912386298 hasAuthorship W2912386298A5047724596 @default.
- W2912386298 hasAuthorship W2912386298A5052415437 @default.
- W2912386298 hasAuthorship W2912386298A5053088701 @default.
- W2912386298 hasAuthorship W2912386298A5055052720 @default.
- W2912386298 hasAuthorship W2912386298A5068657718 @default.
- W2912386298 hasAuthorship W2912386298A5069793228 @default.
- W2912386298 hasAuthorship W2912386298A5076026606 @default.
- W2912386298 hasAuthorship W2912386298A5086609118 @default.
- W2912386298 hasConcept C126322002 @default.
- W2912386298 hasConcept C127413603 @default.
- W2912386298 hasConcept C164705383 @default.
- W2912386298 hasConcept C168563851 @default.
- W2912386298 hasConcept C2777015399 @default.
- W2912386298 hasConcept C2777094939 @default.
- W2912386298 hasConcept C2777628954 @default.
- W2912386298 hasConcept C2777736543 @default.
- W2912386298 hasConcept C2777790613 @default.
- W2912386298 hasConcept C2779134260 @default.
- W2912386298 hasConcept C2779483572 @default.
- W2912386298 hasConcept C2780645631 @default.
- W2912386298 hasConcept C2908647359 @default.
- W2912386298 hasConcept C3020199598 @default.
- W2912386298 hasConcept C50382708 @default.
- W2912386298 hasConcept C541997718 @default.
- W2912386298 hasConcept C71924100 @default.
- W2912386298 hasConcept C78519656 @default.
- W2912386298 hasConcept C99454951 @default.
- W2912386298 hasConceptScore W2912386298C126322002 @default.
- W2912386298 hasConceptScore W2912386298C127413603 @default.
- W2912386298 hasConceptScore W2912386298C164705383 @default.
- W2912386298 hasConceptScore W2912386298C168563851 @default.
- W2912386298 hasConceptScore W2912386298C2777015399 @default.
- W2912386298 hasConceptScore W2912386298C2777094939 @default.
- W2912386298 hasConceptScore W2912386298C2777628954 @default.
- W2912386298 hasConceptScore W2912386298C2777736543 @default.
- W2912386298 hasConceptScore W2912386298C2777790613 @default.
- W2912386298 hasConceptScore W2912386298C2779134260 @default.
- W2912386298 hasConceptScore W2912386298C2779483572 @default.
- W2912386298 hasConceptScore W2912386298C2780645631 @default.
- W2912386298 hasConceptScore W2912386298C2908647359 @default.
- W2912386298 hasConceptScore W2912386298C3020199598 @default.
- W2912386298 hasConceptScore W2912386298C50382708 @default.
- W2912386298 hasConceptScore W2912386298C541997718 @default.
- W2912386298 hasConceptScore W2912386298C71924100 @default.
- W2912386298 hasConceptScore W2912386298C78519656 @default.
- W2912386298 hasConceptScore W2912386298C99454951 @default.
- W2912386298 hasIssue "Suppl_1" @default.
- W2912386298 hasLocation W29123862981 @default.
- W2912386298 hasOpenAccess W2912386298 @default.
- W2912386298 hasPrimaryLocation W29123862981 @default.
- W2912386298 hasRelatedWork W1970259871 @default.
- W2912386298 hasRelatedWork W1974609923 @default.
- W2912386298 hasRelatedWork W2054688520 @default.
- W2912386298 hasRelatedWork W2063470095 @default.
- W2912386298 hasRelatedWork W2080539874 @default.
- W2912386298 hasRelatedWork W2119076215 @default.
- W2912386298 hasRelatedWork W2142028965 @default.
- W2912386298 hasRelatedWork W2411523883 @default.
- W2912386298 hasRelatedWork W2753217352 @default.
- W2912386298 hasRelatedWork W3044619397 @default.
- W2912386298 hasVolume "50" @default.